Source:http://linkedlifedata.com/resource/pubmed/id/11219495
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2001-2-21
|
| pubmed:abstractText |
Recent studies have shown that gene therapy with type I interferon (IFN) in an adenovirus vector is a powerful tool to suppress the growth of human tumors transplanted in immune-deficient mice. However, in these studies the host immune-mediated effects, which may be important in mediating the long-term control of tumor growth by these cytokines, was not studied. In this paper, we evaluate the antitumor efficacy of different adenoviral vectors containing mouse IFN-alpha genes (i.e., a first-generation replication-defective vector containing IFN-alpha1 and two different second-generation vectors containing IFN-alpha2) in immunocompetent DBA/2 mice transplanted with highly metastatic Friend leukemic cells resistant in vitro to type I IFN. We found that injection of all the different adenovirus vectors containing mouse IFN-alpha( genes resulted in a marked antitumor response in mice transplanted either subcutaneously or intravenously with IFN-resistant Friend leukemic cells compared to tumor-bearing animals inoculated with a control vector. Tumor growth inhibition after injection of IFN-adenovirus vectors was associated with a prolonged presence of high IFN levels in the sera of the injected mice. Suppression of metastatic tumor growth was also observed after a single injection of the IFN--adenovirus recombinant vectors, whereas a comparable antitumor response generally required several injections of high doses of IFN. Altogether, these results demonstrate that IFN--adenoviral vectors can efficiently inhibit metastatic tumor growth by host-mediated mechanisms and suggest that adenovirus-mediated IFN-alpha gene therapy may represent an attractive alternative to the conventional clinical use of this cytokine, which generally requires multiple injections of high IFN doses for a prolonged period of time.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0929-1903
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
63-72
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11219495-Adenoviridae,
pubmed-meshheading:11219495-Animals,
pubmed-meshheading:11219495-Friend murine leukemia virus,
pubmed-meshheading:11219495-Gene Therapy,
pubmed-meshheading:11219495-Genetic Vectors,
pubmed-meshheading:11219495-Injections, Intraperitoneal,
pubmed-meshheading:11219495-Injections, Intravenous,
pubmed-meshheading:11219495-Interferon-alpha,
pubmed-meshheading:11219495-Lac Operon,
pubmed-meshheading:11219495-Leukemia, Experimental,
pubmed-meshheading:11219495-Liver Neoplasms, Experimental,
pubmed-meshheading:11219495-Male,
pubmed-meshheading:11219495-Mice,
pubmed-meshheading:11219495-Mice, Inbred DBA,
pubmed-meshheading:11219495-Mice, Nude,
pubmed-meshheading:11219495-Neoplasm Metastasis,
pubmed-meshheading:11219495-Neoplasm Transplantation,
pubmed-meshheading:11219495-Survival Analysis,
pubmed-meshheading:11219495-Transfection,
pubmed-meshheading:11219495-Tumor Cells, Cultured
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.
|
| pubmed:affiliation |
Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|